PBH logo

Prestige Consumer Healthcare Inc. Stock Price

NYSE:PBH Community·US$2.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

PBH Share Price Performance

US$48.48
-29.06 (-37.48%)
US$66.80
Fair Value
US$48.48
-29.06 (-37.48%)
27.4% undervalued intrinsic discount
US$66.80
Fair Value
Price US$48.48
AnalystConsensusTarget US$66.80
AnalystHighTarget US$75.00
AnalystLowTarget US$50.00

PBH Community Narratives

·
Fair Value US$66.8 27.4% undervalued intrinsic discount

PBH: Share Buyback And Cash Flow Will Drive Future Upside

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$75 35.4% undervalued intrinsic discount

Eye Care Capacity Investments And E Commerce Expansion Will Support Long Term Consumer Health Strength

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$50 3.0% undervalued intrinsic discount

OTC Health Demand And Eye Care Supply Efforts Will Support Steady Future Performance

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$66.8
27.4% undervalued intrinsic discount
Revenue
9.21% p.a.
Profit Margin
19.37%
Future PE
12.55x
Price in 2029
US$81.6

Trending Discussion

Updated Narratives

PBH logo

PBH: Future Upside Will Rely On Successful OTC Wellness Integration

Fair Value: US$75 35.4% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
PBH logo

PBH: Future Brand Acquisitions And Buybacks Will Drive Upside Potential

Fair Value: US$66.8 27.4% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
PBH logo

OTC Health Demand And Eye Care Supply Efforts Will Support Steady Future Performance

Fair Value: US$50 3.0% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with adequate balance sheet.

1 Risk
4 Rewards

Prestige Consumer Healthcare Inc. Key Details

US$1.1b

Revenue

US$482.8m

Cost of Revenue

US$605.9m

Gross Profit

US$415.6m

Other Expenses

US$190.3m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 06, 2026
4.02
55.65%
17.48%
52.8%
View Full Analysis

About PBH

Founded
1996
Employees
890
CEO
Ronald Lombardi
WebsiteView website
www.prestigebrands.com

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Recent PBH News & Updates

Narrative Update Jul 02

PBH: Future Upside Will Rely On Successful OTC Wellness Integration

Analysts have revised their price target for Prestige Consumer Healthcare from $81.00 to $75.00, citing updated assumptions regarding revenue growth, profit margins, and a lower projected future P/E multiple. What’s in the News for Prestige Consumer Healthcare Prestige Consumer Healthcare completed a US$1.045b cash acquisition of the OTC Wellness Business, including the Breathe Right brand, financed primarily with a term loan and cash on hand, according to the amended material event report.

Recent updates

No updates